Loading
A phase 3 trial of Pemetrexed, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) is a phase 3 interventional study registered as NCT05722015 by Merck Sharp & Dohme LLC, with 377 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2024-07-12. Interventions recorded: Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel. Conditions listed: Metastatic Non-small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
377 enrolled.
geometric CV 40.41%; Figures from the ClinicalTrials.gov results section (first posted 2025-07-28), not from a publication · geometric CV 26.23%
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Doseprimary | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | 245 | 1633.24 μg·day/ml | - | <0.00001 | link |
| Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy | 126 | 1437.58 μg·day/ml |
Shares Filgrastim (G-CSF), Pemetrexed, Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Pemetrexed, Merck & Co. (MSD), Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Merck & Co. (MSD), Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.